Serious infections significantly increase the mortality risk among adults with chronic liver disease, including those without cirrhosis.

Oseltamivir treatment during influenza episodes is associated with a reduced risk for serious neuropsychiatric events among children and teens.

Electronic cigarette (e-cigarette) flavor restriction policies are associated with reductions in e-cigarette use.

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

In patients with high-risk OSA, CPAP improves cardiovascular outcomes, while harm may be seen in those with low-risk OSA.

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Spencer C. Payne, M.D., from the University of Virginia in Charlottesville, and colleagues updated the guidelines published in 2015 to address quality improvement opportunities for managing adult ...

The FDA has granted accelerated approval to Hernexeos for the treatment of adults with unresectable or metastatic non-squamous NSCLC.

Notable Drug Approvals.

A composite score of 6-minute walk test (6MWT) parameters can predict patient outcomes in idiopathic pulmonary fibrosis (IPF).

COVID-19 vaccination during 2020 to 2024 was beneficial, but estimates are more conservative than previous calculations that focused on the first year of vaccinations.

In patients with asthma, long-term FEV1 reduction may be independently predicted by high BMI, which is a modifiable risk factor.